Pamiparib in combination with tislelizumab in patients with advanced solid tumors: results from the dose-escalation stage of a multicenter, open-label, phase 1a/b trial

Michael Friedlander, MBChB,¹ Tarek Meniawy, PhD,² Ben Markman, MBBS,³ Linda Mileshkin, MD,⁴ Paul Harnett, MBBS,⁵ Michael Millward, MBBS,² Joanne Lundy, MBBS,³ Alison Freimund, MBBS,⁴ Christie Norris, RN,¹ Song Mu, PhD,⁶ John Wu, PhD,⁶ Virginia Paton, PharmD,⁶ Bo Gao, PhD^5
1Department of Medical Oncology, Nelune Comprehensive Cancer Centre, University of New South Wales Clinical School, Prince of Wales Hospital, Sydney, NSW, Australia; ²Linear Clinical Research, Perth, WA, Australia; ³Monash Health and Monash University, Melbourne, VIC, Australia; ⁴Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ⁵Westmead Hospital, Sydney, NSW, Australia; ⁶BeiGene, San Mateo, CA, USA

These edited and reformatted materials are for demonstrational purposes only. The content, edits and layout were not approved by any authors.